UA105073C2 - Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень - Google Patents

Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень

Info

Publication number
UA105073C2
UA105073C2 UAA201206559A UAA201206559A UA105073C2 UA 105073 C2 UA105073 C2 UA 105073C2 UA A201206559 A UAA201206559 A UA A201206559A UA A201206559 A UAA201206559 A UA A201206559A UA 105073 C2 UA105073 C2 UA 105073C2
Authority
UA
Ukraine
Prior art keywords
composition
inflammatory disorders
treating inflammatory
fractalkine antibody
antibody
Prior art date
Application number
UAA201206559A
Other languages
English (en)
Russian (ru)
Inventor
Міюкі Нісімура
Йосімаса Сакамото
Тецу КАВАНО
Тосіо Імаі
Original Assignee
ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA105073(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. filed Critical ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД.
Publication of UA105073C2 publication Critical patent/UA105073C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Винахід належить до антитіла або його фракталкінзв'язуючого фрагмента, які специфічно зв’язують фракталкін, фармацевтичної композиції, що містить антитіло або його фракталкінзв'язуючий фрагмент, способу отримання антитіла або його фракталкінзв'язуючого фрагмента, фармацевтичної композиції, що містить антитіло або його фракталкінзв'язуючий фрагмент, нуклеїнової кислоти, вектора, клітини-хазяїна та застосування для терапевтичних цілей.
UAA201206559A 2009-10-30 2010-10-28 Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень UA105073C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25652109P 2009-10-30 2009-10-30
PCT/JP2010/069653 WO2011052799A1 (en) 2009-10-30 2010-10-28 Compositions and methods for treating inflammatory disorders

Publications (1)

Publication Number Publication Date
UA105073C2 true UA105073C2 (uk) 2014-04-10

Family

ID=43922220

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201206559A UA105073C2 (uk) 2009-10-30 2010-10-28 Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень

Country Status (31)

Country Link
US (1) US8932592B2 (uk)
EP (1) EP2493930B1 (uk)
JP (2) JP5631991B2 (uk)
KR (2) KR102099596B1 (uk)
CN (1) CN102597003B (uk)
AR (2) AR078796A1 (uk)
AU (1) AU2010312408B2 (uk)
BR (1) BR112012010266A2 (uk)
CA (1) CA2778895C (uk)
CL (2) CL2012001143A1 (uk)
CY (1) CY1121167T1 (uk)
DK (1) DK2493930T3 (uk)
ES (1) ES2698389T3 (uk)
HR (1) HRP20181973T1 (uk)
HU (1) HUE041952T2 (uk)
IL (1) IL219470A (uk)
JO (1) JO3437B1 (uk)
LT (1) LT2493930T (uk)
MX (1) MX2012005052A (uk)
MY (1) MY158481A (uk)
NZ (1) NZ599779A (uk)
PE (1) PE20121645A1 (uk)
PL (1) PL2493930T3 (uk)
PT (1) PT2493930T (uk)
RS (1) RS58142B1 (uk)
RU (1) RU2569109C2 (uk)
SI (1) SI2493930T1 (uk)
TW (1) TWI414308B (uk)
UA (1) UA105073C2 (uk)
WO (1) WO2011052799A1 (uk)
ZA (1) ZA201203002B (uk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
CA2968382A1 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3159007A1 (en) 2015-10-19 2017-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis
JP2017154975A (ja) * 2016-02-29 2017-09-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
JP2018070473A (ja) * 2016-10-26 2018-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物
JP2018177701A (ja) * 2017-04-14 2018-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
WO2020214166A1 (en) * 2019-04-17 2020-10-22 The Governors Of The University Of Alberta Treatment of autoimmune liver disease
JPWO2020218232A1 (uk) 2019-04-23 2020-10-29
CN113087795A (zh) * 2019-12-23 2021-07-09 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
CN116472061A (zh) 2020-10-30 2023-07-21 卫材R&D管理有限公司 药物组合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6114507A (en) 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US6096312A (en) 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
CN1196733A (zh) * 1995-06-30 1998-10-21 持田制药株式会社 抗Fas配体抗体和利用抗Fas配体抗体的测定方法
US7115379B1 (en) 1996-01-24 2006-10-03 Schering Corporation Anti-mammalian CX3C cytokine antibodies
US6548654B1 (en) 1996-01-24 2003-04-15 Schering Corporation DNA encoding mammalian CX3C chemokine genes
US6566503B2 (en) 1996-01-24 2003-05-20 Schering Corporation Mammalian CX3C chemokine
EP0876487B1 (en) 1996-01-24 2008-03-12 Schering Corporation Mammalian cx3c chemokine genes
WO1997042224A1 (en) 1996-05-07 1997-11-13 Millennium Biotherapeutics, Inc. Neurotactin and uses therefor
US6043086A (en) 1996-05-07 2000-03-28 Millenium Biotherapeutics, Inc. Neurotactin and uses therefor
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
US6420121B1 (en) 1998-08-31 2002-07-16 Oregon Health Sciences University Prevention of cell migration initiation with CMV US28 receptor antagonists
JP2001218581A (ja) 1999-11-30 2001-08-14 Eisai Co Ltd モノクローナル抗体の作製法
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
WO2001060406A1 (en) 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US20020192212A1 (en) 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
JP4263391B2 (ja) * 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
AU2002323570A1 (en) 2001-08-30 2003-03-10 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1520586A1 (en) 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases
EP1671648A4 (en) 2003-10-02 2009-07-08 Eisai R&D Man Co Ltd PREVENTION AND TREATMENT OF GVHD
WO2005033115A1 (en) 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
WO2006046739A1 (ja) 2004-10-29 2006-05-04 Eisai R & D Management Co., Ltd. 炎症性疾患治療剤
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
SI2094728T1 (sl) 2006-10-26 2013-06-28 Janssen Biotech, Inc. Postopki za uporabo za humano-adaptivnost monoklonskih protiteles
US20100226925A1 (en) * 2007-09-14 2010-09-09 Amgen Inc. Homogeneous Antibody Populations

Also Published As

Publication number Publication date
AU2010312408B2 (en) 2015-07-09
EP2493930A1 (en) 2012-09-05
LT2493930T (lt) 2019-01-10
WO2011052799A1 (en) 2011-05-05
ES2698389T3 (es) 2019-02-04
AR078796A1 (es) 2011-12-07
AU2010312408A1 (en) 2012-06-21
RU2569109C2 (ru) 2015-11-20
EP2493930A4 (en) 2013-12-04
PT2493930T (pt) 2018-11-29
KR20160066055A (ko) 2016-06-09
CL2012001143A1 (es) 2012-10-05
AR109533A2 (es) 2018-12-19
IL219470A (en) 2017-10-31
CA2778895A1 (en) 2011-05-05
EP2493930B1 (en) 2018-09-19
RS58142B1 (sr) 2019-02-28
US20120213799A1 (en) 2012-08-23
PE20121645A1 (es) 2012-12-06
CA2778895C (en) 2018-08-07
MX2012005052A (es) 2012-05-29
US8932592B2 (en) 2015-01-13
TWI414308B (zh) 2013-11-11
HRP20181973T1 (hr) 2019-01-25
BR112012010266A2 (pt) 2016-12-06
PL2493930T3 (pl) 2019-03-29
CN102597003A (zh) 2012-07-18
JP5631991B2 (ja) 2014-11-26
MY158481A (en) 2016-10-14
CN102597003B (zh) 2016-03-23
KR101627605B1 (ko) 2016-06-07
DK2493930T3 (en) 2018-12-17
CY1121167T1 (el) 2020-05-29
KR102099596B1 (ko) 2020-04-10
JP2015027304A (ja) 2015-02-12
RU2012122203A (ru) 2013-12-10
JP2013509158A (ja) 2013-03-14
JO3437B1 (ar) 2019-10-20
TW201127401A (en) 2011-08-16
KR20120104560A (ko) 2012-09-21
ZA201203002B (en) 2013-06-26
CL2015000114A1 (es) 2015-04-10
NZ599779A (en) 2014-03-28
SI2493930T1 (sl) 2018-12-31
HUE041952T2 (hu) 2019-06-28
IL219470A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
MX2010008096A (es) Anticuerpos de ferroportina y metodos de uso.
MX2012011771A (es) Aptameros para beta-ngf y su uso en el tratamiento de enfermedades y trastornos mediados por beta-ngf.
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
PH12017500864A1 (en) Anti-notch1 antibodies
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2011020783A3 (en) Targeted immunoconjugates
IN2014KN02933A (uk)
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
UA108912C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α
MX2015002873A (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r.
EP4324845A3 (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
PH12016500275A1 (en) Antibodies
IN2014DN08481A (uk)
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
GB2496342A (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
WO2012068317A3 (en) Methods for producing recombinant proteins
PH12015501687A1 (en) Novel binding proteins from pcsk9
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
UA105384C2 (uk) Лікування порушень, пов'язаних з інсулінорезистентністю
FI20115328A (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
WO2011085134A8 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2011103028A3 (en) Compositions and methods for inhibiting mmset